176 related articles for article (PubMed ID: 8962244)
1. Influence of the anti-CD25 monoclonal antibody BT563 on clinical and biological rejection after orthotopic liver transplantation.
Otto G; Hofmann WJ; Gaweco AS; Seelos R; Herfarth C; Meuer S
Transplant Proc; 1996 Dec; 28(6):3210-1. PubMed ID: 8962244
[No Abstract] [Full Text] [Related]
2. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 receptor antibody versus antithymocyte globulin as part of quadruple induction therapy after orthotopic liver transplantation: a randomized study.
Langrehr JM; Guckelberger O; Nüssler N; Radtke A; Lemmens HP; Jonas S; Lohmann R; Tullius S; Steinmüller T; Raakow R; Neumann U; Knoop M; Bechstein WO; Neuhaus P
Transplant Proc; 1996 Dec; 28(6):3204. PubMed ID: 8962241
[No Abstract] [Full Text] [Related]
4. Chronic rejection after orthotopic liver transplantation is increased under induction therapy with interleukin-2 receptor antibody BT563.
Langrehr JM; Lohmann R; Raakow R; Jonas S; Klupp J; Bechstein WO; Neuhaus R; Neuhaus P
Transplant Proc; 2001 May; 33(3):2290-1. PubMed ID: 11377531
[No Abstract] [Full Text] [Related]
5. Effect of anti-IL-2-receptor monoclonal antibody BT 563 in treatment of acute interstitial renal rejection.
Carl S; Wiesel M; Daniel V; Staehler G
Transplant Proc; 1995 Feb; 27(1):854-5. PubMed ID: 7879205
[No Abstract] [Full Text] [Related]
6. [Advances in immunossuppression in liver transplantation].
Olivera-Martínez MA
Rev Invest Clin; 2005; 57(2):237-43. PubMed ID: 16524064
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial.
van Gelder T; Zietse R; Yzermans JN; Rischen-Vos J; Vaessen LM; Weimar W
Transplant Proc; 1996 Dec; 28(6):3221-2. PubMed ID: 8962247
[No Abstract] [Full Text] [Related]
8. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
Calmus Y; Scheele JR; Gonzalez-Pinto I; Jaurrieta EJ; Klar E; Pageaux GP; Scudamore CH; Cuervas-Mons V; Metselaar HJ; Prestele H; Girault D
Liver Transpl; 2002 Feb; 8(2):123-31. PubMed ID: 11862588
[TBL] [Abstract][Full Text] [Related]
9. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P
Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
[No Abstract] [Full Text] [Related]
10. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients.
van Gelder T; Mulder AH; Balk AH; Mochtar B; Hesse CJ; Baan CC; Vaessen LM; Weimar W
J Heart Lung Transplant; 1995; 14(2):346-50. PubMed ID: 7779855
[TBL] [Abstract][Full Text] [Related]
11. BT563 significantly decreases sIL-2R plasma levels despite acute allograft rejection.
Mueller AR; Platz KP; Steinmüller T; Nüssler N; Neumann U; Gerlach H; Stoll C; Bechstein WO; Neuhaus P
Transplant Proc; 1996 Dec; 28(6):3103-5. PubMed ID: 8962203
[No Abstract] [Full Text] [Related]
12. Clinical experience with a monoclonal interleukin-2 receptor antibody (BT 563) for rejection therapy after orthotopic heart transplantation.
Iberer F; Tscheliessnigg KH; Freigassner M; Auer T; Kleinert R; Wasler A; Petutschnigg B; Müller H
Transplant Proc; 1994 Dec; 26(6):3237-9. PubMed ID: 7998128
[No Abstract] [Full Text] [Related]
13. Induction therapy with anti-T-lymphocyte globulin following orthotopic liver transplantation.
Schattenfroh N; Lange D; Bechstein WO; Blumhardt G; Keck H; Langrehr JM; Lohmann R; Neuhaus P
Transplant Proc; 1993 Aug; 25(4):2702. PubMed ID: 8356722
[No Abstract] [Full Text] [Related]
14. [Salvage therapy with anti-IL-2 receptor antibodies in high-risk kidney transplant patients].
Carl S; Wiesel M; Deiss JM; Daniel V; Opelz G; Staehler G
J Urol (Paris); 1997; 103(1-2):7-9. PubMed ID: 9765770
[No Abstract] [Full Text] [Related]
15. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients.
Nashan B; Schlitt HJ; Schwinzer R; Ringe B; Kuse E; Tusch G; Wonigeit K; Pichlmayr R
Transplantation; 1996 Feb; 61(4):546-54. PubMed ID: 8610379
[TBL] [Abstract][Full Text] [Related]
16. Anti-IL-2 receptor BT563 versus placebo: a randomized trial for induction therapy after liver transplantation.
Glanemann M; Langrehr JM; Raakow R; Guckelberger O; Lohmann R; Klupp J; Lobeck H; Schlag H; Keck H; Bechstein WO; Settmacher U; Neuhaus P
Transplant Proc; 1998 Aug; 30(5):2159-60. PubMed ID: 9723425
[No Abstract] [Full Text] [Related]
17. CD4 and CD25 monoclonal antibody cocktail in kidney transplant rejection prophylaxis: clinical results of a pilot study.
Mousson C; Tanter Y; Racadot E; Wijdenes J; Chalopin JM; Chevet D; Hervé P; Rifle G
Transplant Proc; 1995 Apr; 27(2):1727-8. PubMed ID: 7725472
[No Abstract] [Full Text] [Related]
18. Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans.
van Gelder T; Baan CC; Balk AH; Knoop CJ; Holweg CT; van der Meer P; Mochtar B; Zondervan PE; Niesters HG; Weimar W
Transplantation; 1998 Feb; 65(3):405-10. PubMed ID: 9484761
[TBL] [Abstract][Full Text] [Related]
19. IL-2 receptor antibody induction increases the risk for chronic rejection after liver transplantation.
Langrehr JM; Lohmann R; Guckelberger O; Müller AR; Raakow R; Nüssler NC; Klupp J; Pfitzmann R; Jonas S; Settmacher U; Steinmüller T; Neuhaus P
Transplant Proc; 2001; 33(1-2):1433-4. PubMed ID: 11267360
[No Abstract] [Full Text] [Related]
20. Quadruple induction immunosuppression after liver transplantation with interleukin-2 receptor antibody (BT 563) is equally effective and better tolerated than antithymocyte globulin induction therapy.
Neuhaus P; Bechstein WO; Blumhardt G; Steffen R; Keck H; Lemmens P; Langrehr JM; Schlag H
Transplant Proc; 1993 Apr; 25(2):1940-1. PubMed ID: 8470234
[No Abstract] [Full Text] [Related]
[Next] [New Search]
